Hyperuricemia and chronic kidney disease: An enigma yet to be solved

Renal Failure

Volumn 36, Issue 9, 2014, Pages 1351-1359

  Dousdampanis, Periklis ^a   Trigka, Konstantina ^a   Musso, Carlos G ^b   Fourtounas, Costas ^c  

^a Kyanous Stavros Patras   (Greece)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

Chronic kidney disease; Dialysis; Hyperuricemia; Mortality; Renal transplantation

Indexed keywords

URIC ACID;

CARDIOVASCULAR MORTALITY; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; HUMAN; HYPERTENSION; HYPERURICEMIA; INCIDENCE; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; OXIDATIVE STRESS; REVIEW; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; KIDNEY; PATHOPHYSIOLOGY; RISK FACTOR;

HUMANS; HYPERURICEMIA; KIDNEY; KIDNEY TRANSPLANTATION; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; URIC ACID;

EID: 84907445156     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.947516     Document Type: Review

References (149)

1. Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75(Suppl. 5): S13-S16.
2. Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007; 50(2):239-247.
3. Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796-803.
4. Murea M. Advanced kidney failure and hyperuricemia. Adv Chronic Kidney Dis. 2012;19(6):419-424.
5. Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med. 2009; 48(6):415-420.
6. Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013;15(2):307.
7. Bellomo G. Uric acid and chronic kidney disease: A time to act? World J Nephrol. 2013;2(2):17-25.
8. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101-1106.
9. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002; 282(6):F991-F997.
10. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355-360.
11. Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39-42.
12. Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY. Serum uric acid levels show a 'J-shaped' association with all-cause mortality in hemodialysis patients. Nephrol Dial Transplant. 2004; 19(2):457-462.
13. Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011;6(10):2470-2477.
14. Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: A 12-year cohort study. J Am Soc Nephrol. 2005; 16(3):791-799.
15. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204-1211.
16. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407-2413.
17. Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol. 2011; 33(4):352-357.
18. Wang S, Shu Z, Tao Q, Yu C, Zhan S, Li L. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology (Carlton). 2011;16(8):767-776.
19. Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: The Severance cohort study. Nephrol Dial Transplant. 2012;27(5):1831-1835.
20. Kuo CF, Luo SF, See LC, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol. 2011; 40(2):116-121.
21. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169(4):342-350.
22. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642-650.
23. Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: A 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36(7):650-654.
24. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264-272.
25. Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10(6):403-409.
26. Yen CJ, Chiang CK, Ho LC, et al. Hyperuricemia associated with rapid renal function decline in elderly Taiwanese subjects. J Formos Med Assoc. 2009;108(12):921-928.
27. Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006;17(5):1444-1452.
28. Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: A retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153-160.
29. Yang Z, Liang Y, Xi W, Zhu Y, Li C, Zhong R. Association of serum uric acid with lupus nephritis in systemic lupus erythematosus. Rheumatol Int. 2011;31(6):743-748.
30. Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134-146.
31. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221-2228.
32. Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F. MMKD Study Group. Uric acid as a risk factor for progression of nondiabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43(4):347-352.
33. Sánchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283(5):F1105-F1110.
34. Sánchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008;23(4):1179-1185.
35. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269-275.
36. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002; 13(12):2888-2897.
37. Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16(4):549-556.
38. Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227-1233.
39. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51-59.
40. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388-1393.
41. Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl. 2014;25(2):316-320.
42. Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Tsuruoka S. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. Ren Fail. 2014; 36(2):225-231.
43. Wang H, Wei Y, Kong X, Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: A meta-analysis. J Ren Nutr. 2013;23(5):389-396.
44. Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: A systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406-413.
45. Mohandas R, Johnson RJ. Uric acid levels increase risk for new-onset kidney disease. J Am Soc Nephrol. 2008; 19(12):2251-2253.
46. Gonick HC, Rubini ME, Gleason IO, Sommers SC. The renal lesion in gout. Ann Intern Med. 1965;62:667-674.
47. Bluestone R, Waisman J, Klinenberg JR. Chronic experimental hyperuricemic nephropathy. Lab Invest. 1975;33(3):273-279.
48. Waisman J, Mwasi LM, Bluestone R, Klinenberg JR. Acute hyperuricemic nephropathy in rats. An electron microscopic study. Am J Pathol. 1975;81(2):367-378.
49. Zhou Y, Fang L, Jiang L, et al. Uric acid induces renal inflammation via activating tubular NF-kB signaling pathway. PLoS One. 2012;7(6):e39738.
50. Ryu ES, Kim MJ, Shin HS, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013; 304(5):F471-F480.
51. Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP. Renal function in gout patients. Am J Nephrol. 1995;15(1):31-37.
52. Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore). 1960;39:405-467.
53. Nickeleit V, Mihatsch MJ. Uric acid nephropathy and end-stage renal disease - Review of a non-disease. Nephrol Dial Transplant. 1997;12(9):1832-1838.
54. Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med. 2011; 1(1):5-12.
55. Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61(5):943-947.
56. Zhang Y, Yamamoto T, Hisatome I, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signalregulated kinase signal pathways in pancreatic b cells. Mol Cell Endocrinol. 2013;375(1-2):89-96.
57. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991; 266(21):3008-3011.
58. Khitan Z, Kim DH. Fructose: A key factor in the development of metabolic syndrome and hypertension. J Nutr Metab. 2013;2013: 682673.
59. Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol. 2009;297(2):F481-F488.
60. Kim SM, Choi YW, Seok HY, et al. Reducing serum uric acid attenuates TGF-b1-induced profibrogenic progression in type 2 diabetic nephropathy. Nephron Exp Nephrol. 2012;121(3- 4):e109-e121.
61. Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes. 2009; 58(7):1668-1671.
62. Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: Findings from the coronary artery calcification in type 1 diabetes study. Nephrol Dial Transplant. 2010; 25(6):1865-1869.
63. Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up. Diabetes Care. 2010;33(6):1337-1343.
64. Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2008;3(3):706-713.
65. Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes. J Diabetes Complications. 2014;28(2):124-129.
66. Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012; 35(1):99-104.
67. Kim WJ, Kim SS, Bae MJ, et al. High-normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function. J Diabetes Complications. 2014;28(2):130-134.
68. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest. 2001;31(4):318-321.
69. Ito H, Abe M, Mifune M, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One. 2011; 6(11):e27817.
70. Tanaka K, Hara S, Kushiyama A, et al. Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic patients: Critical level of the estimated glomerular filtration rate and the significance of hyperuricemia. Clin Exp Nephrol. 2011;15(3):391-397.
71. Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis. 2010;4(2):128-132.
72. Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58(1):2-7.
73. Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah: A screening analysis. Hypertension. 1991;17(6Pt2):969-976.
74. Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: Data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res. 2001;24(5):531-536.
75. Alper Jr AB, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: The Bogalusa Heart Study. Hypertension. 2005;45(1):34-38.
76. Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: The Olivetti Heart Study. J Hum Hypertens. 1994; 8(9):677-681.
77. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298-303.
78. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42(4):474-480.
79. Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: The atherosclerosis risk in communities study. Hypertension. 2006;48(6):1037-1042.
80. Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27(11):835-841.
81. Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: The Normative Aging Study. Hypertension. 2006;48(6):1031-1036.
82. Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005; 45(1):28-33.
83. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens. 2001; 19(7):1209-1215.
84. Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007; 25(8):1583-1589.
85. Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006;47(5):962-967.
86. Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007; 18(1):287-292.
87. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247-252.
88. Yoshimura A, Adachi H, Hirai Y, et al. Serum uric acid is associated with the left ventricular mass index in males of a general population. Int Heart J. 2014;55(1):65-70.
89. Nitta K, Iimuro S, Imai E, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(5):730-742.
90. Tsioufis C, Chatzis D, Vezali E, et al. The controversial role of serum uric acid in essential hypertension: Relationships with indices of target organ damage. J Hum Hypertens. 2005;19(3): 211-217.
91. Boban M, Kocic G, Radenkovic S, et al. Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren Fail. 2014;36(4):613-618.
92. Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int. 2004;66(1):281-287.
93. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811-1821.
94. Sheikhbahaei S, Fotouhi A, Hafezi-Nejad N, Nakhjavani M, Esteghamati A. Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. Metab Syndr Relat Disord. 2014;12(2):102-109.
95. Sedaghat S, Hoorn EJ, van Rooij FJ, et al. Serum uric acid and chronic kidney disease: The role of hypertension. PLoS One. 2013;8(11):e76827.
96. Jalalzadeh M, Nurcheshmeh Z, Mohammadi R, Mousavinasab N, Ghadiani MH. The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia. J Res Med Sci. 2012;17(11):1039-1046.
97. Pai BH, Swarnalatha G, Ram R, Dakshinamurty KV. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian J Nephrol. 2013;23(4):280-286.
98. Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NUFLASH Trial). Circ J. 2013;77(8):2043-2049.
99. Gois PH, Souza ER. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev. 2013;1: CD008652.
100. Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders - Facts and controversies. Biochem Med (Zagreb). 2012;22(1):63-75.
101. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis. 2000;148(1):131-139.
102. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA. 1981;78(11):6858-6862.
103. Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000; 376(2):333-337.
104. Kurra V, Eräranta A, Jolma P, et al. Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency. Am J Hypertens. 2009;22(9):964-970.
105. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 2008;392(1-2):1-7.
106. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287-1293.
107. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553-3562.
108. Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One. 2011;6(5):e19901.
109. Ling Y, Li XM, Gao X. Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients. Chin Med J (Engl). 2013;126(21):4023-4029.
110. Caravaca F, Martín MV, Barroso S, et al. Serum uric acid and C-reactive protein levels in patients with chronic kidney disease. Nefrologia. 2005;25(6):645-654.
111. Wang Y, Bao X. Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms. Eur J Med Res. 2013;18(1):26.
112. Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20(3):182-187.
113. Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: Molecular mechanisms and clinical implications. J Cardiol. 2012;59(3):235-242.
114. Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007;50(12):2572-2579.
115. Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65(6):2380-2389.
116. Liu WC, Hung CC, Chen SC, et al. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2012;7(4):541-548.
117. Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48(5):761-771.
118. Wen CP, David Cheng TY, Chan HT, et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis. 2010;56(2):273-288.
119. Navaneethan SD, Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1260-1266.
120. Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012;36(4):324-331.
121. Neri L, Rocca Rey LA, Lentine KL, et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: A historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis. 2011; 58(3):398-408.
122. Chung W, Kim AJ, Ro H, Chang JH, Lee HH, Jung JY. Hyperuricemia is an independent risk factor for mortality only if chronic kidney disease is present. Am J Nephrol. 2013; 37(5):452-461.
123. Terawaki H, Nakayama M, Miyazawa E, et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: The Gonryo study. Clin Exp Nephrol. 2013;17(4):549-553.
124. Lee CT, Chua S, Hsu CY, et al. Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers. 2013;34(4):229-235.
125. Antunovic T, Stefanovic A, Ratkovic M, et al. High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients. Int Urol Nephrol. 2013;45(4):1111-1119.
126. Lobo JC, Stockler-Pinto MB, da Nóbrega AC, Carraro-Eduardo JC, Mafra D. Is there association between uric acid and inflammation in hemodialysis patients? Ren Fail. 2013; 35(3):361-366.
127. Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19(11):2204-2210.
128. Lee SM, Lee AL, Winters TJ, et al. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. Am J Nephrol. 2009;29(2):79-85.
129. Fourtunas C. Perceptions of gout (podagra) during the Byzantine era, with a special focus on a poem by Michael Psellus. J Nephrol. 2013;26(Suppl. 22):110-112.
130. Xia X, He F, Wu X, Peng F, Huang F, Yu X. Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis. Am J Kidney Dis. 2014; 64(2):257-264.
131. Feng S, Jiang L, Shi Y, et al. Uric acid levels and all-cause mortality in peritoneal dialysis patients. Kidney Blood Press Res. 2013;37(2-3):181-189.
132. Dong J, Han QF, Zhu TY, et al. The associations of uric acid, cardiovascular and all-cause mortality in peritoneal dialysispatients. PLoS One. 2014;9(1):e82342.
133. Mazali FC, Mazzali M. Uric acid and transplantation. Semin Nephrol. 2011;31(5):466-471.
134. Einollahi B, Einollahi H, Nafar M, Rostami Z. Prevalence and risk factors of hyperuricemia among kidney transplant recipients. Indian J Nephrol. 2013;23(3):201-205.
135. Alpay N, Ozkok A, Caliskan Y, et al. Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients. Clin Exp Nephrol. 2014 [Epub ahead of print]. doi: 10.1007/ s10157-014-0939-4.
136. Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Uric acid levels have no significant effect on renal function in adult renal transplant recipients: Evidence from the symphony study. Clin J Am Soc Nephrol. 2009;4(10):1655-1660.
137. Gores PF, Fryd DS, Sutherland DE, Najarian JS, Simmons RL. Hyperuricemia after renal transplantation. Am J Surg. 1988; 156(5):397-400.
138. Akgul A, Bilgic A, Ibis A, Ozdemir FN, Arat Z, Haberal M. Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? Transplant Proc. 2007;39(4):1023-1026.
139. Akalin E, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008;86(5):652-658.
140. Gerhardt U, Grosse Hüttmann M, Hohage H. Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clin Transplant. 1999; 13(5):375-379.
141. Armstrong KA, Johnson DW, Campbell SB, Isbel NM, Hawley CM. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation. 2005;80(11):1565-1571.
142. Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol. 2009;103(6):867-871.
143. Min SI, Yun IJ, Kang JM, et al. Moderate-to-severe early-onset hyperuricaemia: A prognostic marker of long-term kidney transplant outcome. Nephrol Dial Transplant. 2009;24(8):2584-2590.
144. Choi JY, Kwon OJ. The association between serum uric acid levels at 3 months after renal transplantation and the graft outcome in living donor renal transplantation. Transplant Proc. 2013;45(4):1548-1552.
145. Huang Y, Li YL, Huang H, Wang L, Yuan WM, Li J. Effects of hyperuricemia on renal function of renal transplant recipients: A systematic review and meta-analysis of cohort studies. PLoS One. 2012;7(6):e39457.
146. Weng SC, Shu KH, Tarng DC, et al. Uric acid is highly associated with kidney allograft survival in a time-varying analysis. Transplant Proc. 2014;46(2):505-510.
147. Hart A, Jackson S, Kasiske BL, et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: Post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. Transplantation. 2014;97(10):1066-1071.
148. Saglam F, Celik A, Sarioglu S, et al. Hyperuricemia influences chronic cyclosporine nephropathy. Transplant Proc. 2008; 40(1):167-170.
149. Boratyńska M, Karbowska A, Klinger M. The effect of hyperuricemia on endothelial biomarkers and renal function in kidney allograft recipients. Transplant Proc. 2010;42(10): 4074-4077.